Title: determination of LMP744 (NSC 706744) levels in human plasma and urine samples from an NCI phase I trial.POP: 04/01/2017 - 03/31/2018
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
University Of Pittsburgh - Of The Commonwealth System Of Higher Education UEI MKAGLD59JRL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $274,027
Award facts
- Opportunity
-
- N02CM6700011 Solicitation number
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients Award Notice · Posted Feb 22, 2016
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients Award Notice · Posted Feb 5, 2016
- Preclinical Pharmacokinetic and Pharmacological Studies Being Developed for Cancer Patients Award Notice · Posted Oct 6, 2015
- Contract value 67% obligated
-
- $274,027.33 Current, with exercised options
- $408,140.33 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Pittsburgh, PA 15213, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$3,221 | |
| Exercise an Option | $134,113 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $143,135 |
About this award
This is a federal contract award made by the National Cancer Institute (NCI), a civilian agency, to the University of Pittsburgh. The contract is for the determination of LMP744 (NSC 706744) levels in human plasma and urine samples from an NCI Phase I trial. The contract has a ceiling value of $408,140.33 and a period of performance from April 1, 2017 to June 30, 2022. It is a delivery order contract under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients master IDIQ. The contract does not have a set-aside designation. The University of Pittsburgh, a state-related research university in Pennsylvania, is the prime contractor and there are no major subcontractors mentioned. This contract supports the NCI's broader efforts in preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients.
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Cancer Institute (National Institutes of Health) on April 10, 2017.
How much is contract HHSN26100002 worth?
The government has obligated $274,027 on HHSN26100002. Its potential value, with all options, is $408,140.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201600022I, an indefinite delivery contract, on Pharmacokinetic and Pharmacology Evaluations for Cancer Patients.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award